Shen Nan

Director of the Department of Rheumatology at Renji Hospital affiliated with Shanghai Jiao Tong University School of Medicine; Director of the Sino-Australian Joint Research Center for Personalized Immunology; Director of the Shanghai Clinical Medical Center for Autoimmune Diseases; and Director of the Shanghai Institute of Rheumatology. Head of the Molecular Rheumatology Research Group at the Institute of Health Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences; Member of the Planning Committee of the American College of Rheumatology (the only member from the Asia-Pacific region). Chief Scientist of the National 973 Program, recipient of the National Natural Science Foundation of China's Outstanding Youth Fund, a leading talent in the National "Ten Thousand Talents Program," and a leading talent in Shanghai. Doctor of Medicine, Doctor of Science. Long-term research on the pathogenesis and treatment of systemic lupus erythematosus (SLE). Pioneered the discovery that abnormal activation of the type I interferon pathway is the main molecular phenotype of lupus, and established a novel biomarker analysis system for clinical subgroup classification and efficacy evaluation of lupus; in 2024, the mechanism by which ZEB2 drives the formation of pathogenic B cells in lupus was revealed for the first time in *Science*. Published over 100 SCI-indexed papers in journals such as Nature Medicine and PNAS. Selected for the ELSEVIER China Highly Cited Researchers list in 2016. Serves as Associate Editor of the internationally authoritative SLE textbook DUBOIS' Lupus Erythematosus, and received the Edmund Dubois Memorial Award from the American College of Rheumatology. Also serves as Associate Editor and editorial board member for several important international journals in the field of rheumatology.